DNA (cytosine-5)-methyltransferase 3A (DNMT3A)
Homo sapiens — UniProt Q9Y6K1
Data last refreshed: (UniProt release unknown)
Key facts
DNA (cytosine-5)-methyltransferase 3A (DNMT3A) is a protein from Homo sapiens identified by UniProt accession Q9Y6K1, 912 residues long. MolForge cross-references it against 4 known binders and 782 disease associations.
- UniProt accession: Q9Y6K1; gene symbol DNMT3A.
- Organism: Homo sapiens.
- Length: 912 amino acids.
- Approved drugs acting on it (DrugCentral): Azacitidine and Decitabine.
- Top disease associations (Open Targets): acute myeloid leukemia, Tatton-Brown-Rahman overgrowth syndrome and myelodysplastic syndrome.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | DNA (cytosine-5)-methyltransferase 3A |
|---|---|
| UniProt accession | Q9Y6K1 |
| Gene | DNMT3A |
| Organism | Homo sapiens |
| Length | 912 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). Approved drug exists
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs acting on this target (2)
Approved drugs whose DrugCentral mechanism of action is this protein, most potent first.
Disease associations (782)
Diseases linked to this target (Open Targets).
- acute myeloid leukemia · score 0.86
- Tatton-Brown-Rahman overgrowth syndrome · score 0.84
- myelodysplastic syndrome · score 0.76
- chronic myelomonocytic leukemia · score 0.65
- Heyn-Sproul-Jackson syndrome · score 0.65
- diffuse large B-cell lymphoma · score 0.58
- refractory anemia with excess blasts · score 0.58
- neoplasm · score 0.57
- genetic disorder · score 0.53
- anemia · score 0.50
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9Y6K1-F1 | alphafold | PREDICTED | 72.94 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9Y6K1.
Amino-acid sequence (912 residues)
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which approved drugs target DNMT3A?
DrugCentral lists 2 approved drugs whose mechanism of action is DNMT3A: Azacitidine and Decitabine.
Which diseases are associated with DNMT3A?
The strongest Open Targets associations for DNMT3A are acute myeloid leukemia, Tatton-Brown-Rahman overgrowth syndrome, myelodysplastic syndrome, chronic myelomonocytic leukemia and Heyn-Sproul-Jackson syndrome.
How long is the DNMT3A protein?
The Homo sapiens DNMT3A protein (UniProt Q9Y6K1) is 912 amino acids long.
Browse: Targets: D · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9Y6K1 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9Y6K1 — predicted 3D structure (CC BY 4.0)
- DrugCentral — approved drugs and mechanism-of-action links (CC BY-SA 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.